IntestoGuard: new drug tested for dogs with Inflammatory Bowel Disease

Species: 
Dog
Area of Study: 
Internal Medicine

Purpose of Study: 

In this study we want to evaluate the clinical efficacy of a new product (Intesto-Guard™) in dogs with chronic diarrhea (enteropathy).

Intesto–Guard™ contains a binding protein and a combination of probiotics and prebiotics, which may reduce and control clinical signs of chronic diarrheal cases.

The purpose of this study is to compare the outcome of 2 groups of dogs with chronic enteropathy:

  • One group treated with hypoallergenic diet, together with Intesto–Guard™.
  • One group treated with the hypoallergenic diet and a placebo (no medication).
  • If the dog does not get better, rescue treatment with an immunosuppressor (cyclosporin) will be initiated.

Cyclosporine and hypoallergenic diet are each part of standard management of a chronic enteropathy (IBD) in a dog.

Eligibility: 

Your dog is eligible for this trial if he has clinical signs compatible with Inflammatory Bowel Disease, and your veterinarian refers him/her to ISU College of Veterinay Medicine for more adanced investigations.

 

Exclusion: 

Your dog cannot participate in this study if he/she has Protein Losing Enteropathy (PLE)

Client Responsibilities: 

If you agree to have your animal participate in this study, the participation will last for 3 visits at the Lloyd Veterinary Medical Center, over a 6 week-period.  

The visits will occur as follows:

  • Visit 1: Day of enrollment.

Your dog will be randomly assigned to one of the 3 groups mentioned here above.

This visit will occur as follows:

  • A physical examination will be performed.
    • The following samples will be collected:
      • Blood: about 6mL of blood will be sampled (about half a tablespoon).
      • Feces will be collected from a voided sample.
      • Urine will be collected either by free-catch or cystocentesis (insertion of a small needle into the bladder through the abdomen).
    • A GI endoscopy will also be performed for diagnostic purposes, during which intestinal samples (called biopsies) will be taken to assess your dog’s condition.
    • An abdominal ultrasound will be performed.
    • An hypoallergenic diet will be provided for the entire study period.

All of the above, including the diet, is part of routine management of a dog with chronic enteropathy, regardless of the study.

  • Visit 2: Day 14

On this visit, a physical examination will be performed, and blood, urine and feces will be collected again, as described above.

  • Visit 3: Day 42

This visit will occur exactly like Visit 1. The same samples will be collected, and the GI endoscopy will be repeated as well as the abdominal ultrasound.

During the study, you will also be required to keep track of each time the treatment is given, on a specific form that will be provided to you.

If your dog does not show a significant improvement of his/her condition at Visit 2, he/she will be removed from his/her group and be prescribed cyclosporine (immuno-suppressor). He/she will remain enrolled in the study for the full 6 weeks course.

Client Benefits: 

Each study participant will receive a study participation credit, not to exceed 4000$ off the total bill after completion of the third visit.

Any adverse effects attributable to the test product will be medically managed by a study internist at no cost to you.

You will be responsible for any costs associated with the normal course of treatment, and unrelated medical conditions.

Contact: 

Dr Agnes Bourgois-Mochel: 515-291-9866

Dr Al Jergens: 515-294-4900